Table 3.
Patient series for microdissection.
| Total n = 12 | Non-smoker controls | COPD stage 4 | |
|---|---|---|---|
| Subjects, n (Female/Male) | 6 (4/2) | 6 (5/1) | ns |
| Age | 59 ± 9 | 58 ± 4 | ns |
| BMI (kg.m − 2) | 27 ± 6 | 24 ± 5 | ns |
| Smoking history (never /former /current) | 6/0/0 | 0/6/0 | p<0•001 |
| Pack-years | 0 ± 0 | 38 ± 12 | p<0•01 |
| FEV1 pre-bronchodilation (% of PV) | 91 ± 15 | 22 ± 8 | p<0•01 |
| FEV1 post-bronchodilation (% of PV) | NA | 24 ± 8 | NA |
| FEV1 absolute increase after bronchodilation, ml | NA | 52 ± 73 | NA |
| FVC pre-bronchodilation (% of PV) | 97 ± 13 | 62 ± 11 | p<0•01 |
| FVC post-bronchodilation (% of PV) | NA | 67 ± 10 | NA |
| FEV1/FVC pre-bronchodilation ratio (%) | 77 ± 6 | 45 ± 16 | p<0•01 |
| FEV1/FVC post-bronchodilation ratio (%) | NA | 42 ± 15 | NA |
| DLCO (% of PV) | 89 ± 24 | 28 ± 17 | p<0•01 |
| Inhaled corticosteroids, n | 0 | 4 | p<0,05 |
| Inhaled corticosteroids mean dosage, µg (BDP equivalent) | NA | 950 ± 900 | NA |
| Inhaled corticosteroids, device (metered-dose inhalers / dry powder inhalers) | NA | 0/4 | NA |
Radiological findings Bronchiectasis Emphysema
|
0/6 0/6 |
1/6 6/6 1 5 |
|
Surgical indication Cancer
|
6/6 2 2 2 0/6 |
0/6 6/6 6 |
Data are presented as mean ± SD, unless otherwise stated. Demographic data, lung function tests, smoking history, and inhaled corticotherapy as well as radiological findings and surgery indication are stated for the patient groups, classified according to smoking history and the presence of airflow limitation. Patients with other lung diseases (e.g., asthma) were excluded from the study.
BMI, body mass index; COPD, chronic obstructive pulmonary disease; DLCO, diffusing capacity of the lung for CO; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; PV, predicted values.
ns, not significant.